Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Price, Quote, News and Overview

NASDAQ:INKT - Nasdaq - US6036932019 - Common Stock - Currency: USD

7.452  -0.41 (-5.19%)

INKT Quote, Performance and Key Statistics

MINK THERAPEUTICS INC

NASDAQ:INKT (4/30/2025, 8:14:14 PM)

7.452

-0.41 (-5.19%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.79
52 Week Low4.56
Market Cap29.58M
Shares3.97M
Float1.00M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/bmo
IPO10-15 2021-10-15


INKT short term performance overview.The bars show the price performance of INKT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

INKT long term performance overview.The bars show the price performance of INKT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of INKT is 7.452 USD. In the past month the price decreased by -19.2%. In the past year, price decreased by -23.98%.

MINK THERAPEUTICS INC / INKT Daily stock chart

INKT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19 345.13B
AMGN AMGEN INC 14.68 156.41B
GILD GILEAD SCIENCES INC 13.76 132.82B
VRTX VERTEX PHARMACEUTICALS INC 1756.9 130.98B
REGN REGENERON PHARMACEUTICALS 13.51 65.46B
ARGX ARGENX SE - ADR 339.55 39.39B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.24B
ONC BEIGENE LTD-ADR N/A 28.00B
BNTX BIONTECH SE-ADR N/A 25.04B
NTRA NATERA INC N/A 20.40B
SMMT SUMMIT THERAPEUTICS INC N/A 17.79B
BIIB BIOGEN INC 7.35 17.72B

About INKT

Company Profile

INKT logo image MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The company is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Company Info

MINK THERAPEUTICS INC

149 Fifth Avenue, Suite 500

New York City NEW YORK US

Employees: 31

Company Website: https://www.minktherapeutics.com

Investor Relations: https://investor.minktherapeutics.com/

Phone: 12129948250

MINK THERAPEUTICS INC / INKT FAQ

What is the stock price of MINK THERAPEUTICS INC today?

The current stock price of INKT is 7.452 USD. The price decreased by -5.19% in the last trading session.


What is the ticker symbol for MINK THERAPEUTICS INC stock?

The exchange symbol of MINK THERAPEUTICS INC is INKT and it is listed on the Nasdaq exchange.


On which exchange is INKT stock listed?

INKT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MINK THERAPEUTICS INC stock?

10 analysts have analysed INKT and the average price target is 49.3 USD. This implies a price increase of 561.57% is expected in the next year compared to the current price of 7.452. Check the MINK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MINK THERAPEUTICS INC worth?

MINK THERAPEUTICS INC (INKT) has a market capitalization of 29.58M USD. This makes INKT a Nano Cap stock.


How many employees does MINK THERAPEUTICS INC have?

MINK THERAPEUTICS INC (INKT) currently has 31 employees.


What are the support and resistance levels for MINK THERAPEUTICS INC (INKT) stock?

MINK THERAPEUTICS INC (INKT) has a support level at 7.24 and a resistance level at 7.51. Check the full technical report for a detailed analysis of INKT support and resistance levels.


Should I buy MINK THERAPEUTICS INC (INKT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MINK THERAPEUTICS INC (INKT) stock pay dividends?

INKT does not pay a dividend.


When does MINK THERAPEUTICS INC (INKT) report earnings?

MINK THERAPEUTICS INC (INKT) will report earnings on 2025-05-12, before the market open.


What is the Price/Earnings (PE) ratio of MINK THERAPEUTICS INC (INKT)?

MINK THERAPEUTICS INC (INKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).


What is the Short Interest ratio of MINK THERAPEUTICS INC (INKT) stock?

The outstanding short interest for MINK THERAPEUTICS INC (INKT) is 2.65% of its float. Check the ownership tab for more information on the INKT short interest.


INKT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

INKT Financial Highlights

Over the last trailing twelve months INKT reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -192.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -188.52%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-287.5%
Sales Q2Q%N/A
EPS 1Y (TTM)-192.42%
Revenue 1Y (TTM)N/A

INKT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to INKT. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners2.09%
Ins Owners7.95%
Short Float %2.65%
Short Ratio3.36
Analysts
Analysts86
Price Target49.3 (561.57%)
EPS Next Y-38.99%
Revenue Next YearN/A